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Abstract:
Background:
The non-invasive assessment  of  pulmonary haemodynamics  during exercise  provides  complementary data  for  the  evaluation of
exercise tolerance in patients with COPD.
Methods:
Exercise echocardiography in the semi-supine position was performed in 27 patients with COPD (C) with a forced expiratory volume
in  one  second  (FEV1)  of  36±12%  predicted  and  13  age  and  gender-matched  non-COPD  subjects  (NC).  COPD  patients  also
underwent cardiopulmonary exercise testing with gas exchange detection (CPET). Furthermore, serum high sensitive C-reactive
protein (hsCRP), a marker of systemic inflammation, was also measured.
Results:
The maximal work rate (WRmax) and aerobic capacity (VO2peak) were significantly reduced (WRmax: 77±33 Watt, VO2peak:
50±14 %pred) in COPD. Pulmonary arterial systolic pressure (PAPs) was higher in COPD versus controls both at rest (39±5 vs. 31±2
mmHg, p<0.001), and at peak exercise (72±12 vs. 52±8 mmHg, p<0.001). In 19 (70%) COPD patients, the increase in PAPs was
above 22 mmHg. The change in  pressure  (dPAPs)  correlated with hsCRP (r2=0.53,  p<0.0001)  and forced vital  capacity  (FVC)
(r2=0.18, p<0.001).
Conclusion:
PAPs at rest and during exercise were significantly higher in COPD patients and correlated with higher hsCRP. This may indicate a
role for systemic inflammation and hyperinflation in the pulmonary vasculature in COPD.
The study was registered at ClinicalTrials.gov webpage with NCT00949195 registration number.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) seems to be not only a functional disorder of the lungs, but it may
have systemic effects as well [1]. Extrapulmonary  manifestations  have  been  described in  skeletal  muscles,  bones
 and  the  cardiovascular system  [2].  It  is postulated  that  low  intensity  chronic inflammation may result in oxidative
stress and endothelial dysfunction, ischemic heart disease or stroke [3, 4].
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The level of high sensitive C-reactive protein (hsCRP) may be a marker for systemic inflammation [5]. Higher value
of hsCRP has been identified in chronic heart failure and cardiovascular disease [6]. Pulmonary hypertension (PH), a
common finding in COPD, has a major impact on the quality of life and survival [7 - 9]. Arterial PH was associated
with elevated serum level of CRP, IL-6, TNF and correlation was observed between C-reactive protein and endothelin-1
levels, showing the potential  role of systemic  inflammation in  the pathogenesis  of pulmonary  hypertension in COPD
[8, 10, 11].
The pathogenesis of PH in COPD is complex. Alveolar hypoxia results in pulmonary arterial vasoconstriction in
order to provide optimal alveolar ventilation-perfusion ratio [7, 12]. Hypoxia may have both a direct and indirect effect
on pulmonary vasculature (through transmitters and biogen amines) [8, 12]. Pulmonary hypertension is present in a
substantial part of COPD patients (and is found in up to 50% according to diagnostic modalities). Otherwise, severe
pulmonary hypertension is manifested only in 5% of these patients [13 - 16]. However, pulmonary pressure can increase
significantly during exercise [17 - 19], which may have consequences in assessment of exercise capacity. Pulmonary
pressure increment in an age-dependent way is presented in healthy subjects, otherwise higher increment in COPD may
result higher load on circulation, heart and reduction of exercise tolerance.
We wished to determine whether the increment in PAPs during exercise was related to systemic inflammation in
COPD as assessed by monitoring high sensitive CRP. Furthermore, we sought to clarify the correlation between PAPs
increment during exercise and exercise physiologic variables. Since there is limited data in the literature on pulmonary
arterial  pressure  response  during  exercise  in  healthy  subjects,  in  this  study,  the  change  in  pulmonary  arterial  peak
systolic pressure (PAPs) during exercise in an age and gender-matched non-COPD subject group was also investigated.
MATERIAL AND METHODS
Study Subjects
Twenty-seven stable patients with COPD according to the GOLD criteria and a control group of thirteen age and
gender-matched non-COPD subjects participated in the study (Table 1). The severity of airway obstruction ranged from
severe to very severe in the COPD group [20]. COPD therapy with maximal bronchodilator effect was based on lung
function related GOLD stages. Subjects were screened for hypertension, smoking history, hyperlipidemia and diabetes
mellitus.  Control  subjects  as  an  age-matched  population  had  representative  co-morbidities.  Significant  airway
obstruction or reduction in diffusion capacity was not detected in the non-COPD group. 38 patients with COPD were
initially  screened,  however  eleven  were  excluded  because  the  semi-supine  echocardiography  test  could  not  be
performed, and the tricuspid jet could not be visualized at peak exercise (Fig. 1). The study was approved by the Ethical
Committee of University of Szeged and the patients gave written consent to their participation.
Fig. (1). Flow of participants through each study stage.
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Pulmonary Function and Exercise Testing
Patients performed a series of pulmonary function tests (PFT) (Vmax 229 and Autobox 6200, Sensormedics, Yorba
Linda, California) including spirometry, body plethysmography and diffusion capacity measurement [20, 21]. Normal
values were those of NHANES III standards [21]. Patients inhaled 400μg of salbutamol via a spacer 20 minutes before
testing.
Table 1. Demographics in patients with COPD and in healthy subjects (n=40).
  COPD patients n=27 Non-COPD subjects n=13   p-value
Age (years), mean±SD 58±10 63±5 ns
Male sex(n) 15 (56%) 6 (46%) ns
Height (cm), mean±SD 167±10 170±10 ns
BMI (kg/m2), mean±SD 24±5 26±3 ns
Diabetes
n (%)




14 (52) 5 (38)
<0.05
Smoking history (pack-year), mean±SD 33±12 12±8 <0.05
Hyperlipidemia n (%) 5 (19) 2 (15)  ns
Mean±SD, BMI=body mass index; SD=standard deviation
Immediately following the completion of PFTs, an incremental exercise test was performed on an electronically
braked cycle ergometer (Ergoline-900, Marquette). After a 3-minute rest and a 3-minute constant pedalling at 20W, the
work rate was increased 5 or 10 W/min in ramp profile. The ramp slope was: FEV1 <1.0Litre – 5W/min, FEV1 >1.0Litre
– 10W/min.  Pedalling rate  was kept  constant  at  approximately 60rpm. Pulmonary ventilation (‘VE),  oxygen uptake
(‘VO2)  and  carbon-dioxide  output  (‘VCO2)  were  measured  breath-by-breath  by  a  mass  flow-sensor  and  exercise
metabolic  measurement  system  (Vmax29c,  SensorMedics).  Lactic  acidosis  threshold  (LAT)  was  identified  by  the
modified  V-slope  method  [22].  Heart  rate,  12-lead  ECG  (Cardiosoft,  SensorMedics)  and  oxygen  saturation  by  a
pulsoximeter (SatTrak, SensorMedics) was monitored. Maximal voluntary ventilation was estimated as 40xFEV1 [23].
Breathlessness and leg fatigue were evaluated at peak exercise by modified Borg scale [24].
Resting and stress Doppler echocardiographic studies
Echocardiographic  studies  were  performed  with  a  commercially  available  echocardiographic  system  (Vivid  7
Expert,  General  Electric  Healthcare).  Resting  cardiac  dimensions  were  obtained  by  parasternal  long-axis  M-mode
echocardiography, according to the American Society of Echocardiography standards [25]. These dimensions included
left ventricular end-diastolic diameter, interventricular septal wall and posterior wall thickness, right ventricular outflow
diastolic diameter, and left ventricular end-systolic diameter. Using the apical 4-chamber view, the M-mode cursor was
placed through the junction of the tricuspid valve plane and right ventricular free wall. Tricuspid annular plane systolic
excursion (TAPSE) was determined by the difference in the displacement of the right ventricular base during systole
and diastole. Each parameter was measured off-line in triplicate and averaged. All images were obtained during held
mid-expiration.
All  patients  and  controls  had  normal  left  ventricular  ejection  fraction  (EF  >  55%)  and  no  echocardiographic
evidence  of  significant  right  ventricular  dysfunction.  In  an  effort  to  diagnose  left  ventricular  diastolic  dysfunction
related heart failure, and secondary pulmonary PH, the E/A was recorded. Patients and the control subjects underwent a
standardized multistage semi-supine bicycle exercise study in the recumbent position. Patients and controls pedalled at
constant speed beginning at a workload of 25 W, with an increment of 25 W every 3 minutes. The protocol included
both a low intensity "warm up" and a "cool-down" phase. Doppler evaluation of the tricuspid valve was performed in
the apical four-chamber view. The tricuspid regurgitant jet was localized in the color mode, and then measured in the
continuous wave mode at a sweep speed of 75 mm/sec. To ensure accurate transducer position throughout the exercise,
the location of the continuous wave Doppler cursor was checked intermittently by two dimensional and colour imaging.
We considered tricuspid insufficiency envelopes to be technically adequate when signals were pansystolic and showed
well-defined borders. The maximum tricuspid insufficiency velocity was assigned to the highest coherent boundary on
the spectral wave form. Maximum velocities recorded at rest, at each stage of exercise permitted the calculation of the
transtricuspid gradient and PAPs. By a modification of the Bernoulli formula, the maximum transtricuspid gradient (in
mmHg) was estimated as the product of 4 and the square of the maximum tricuspid insufficiency velocity [26]. PAPs
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was computed as the sum of the transtricuspid gradient and right atrial pressure (PAPs = 4V2+right atrial pressure) [27].
Table  2.  Lung  function  and  resting  and  exercise  echocardiography  variables  in  patients  with  COPD and  in  non-COPD
subjects (n=40).
  COPD patients (n=27) Non-COPD subjects (n=13) p-value
Lung function variables      
FEV1 (L) 1.01±0.38 2.84±0.74 <0.001
FEV1 (%pred) 36±12 103±14 <0.001
FVC (L) 2.45±0.71 3.77±0.94 <0.001
FVC (%pred) 73±18 113±20 <0.001
FEV1/FVC (%) 42±11 77±6 <0.001
TLC (%pred) 117±21 104±13 <0.05
VC (%pred) 77±18 114±18 <0.001
IC (L) 1.64±0.48 2.57±0.43 <0.001
FRC (%pred) 164±42 111±18 <0.001
RV (%pred) 199±57 100±18 <0.001
RV/TLC (%) 60±10 37±6 <0.001
DLCO (%pred) 41±15 88±5 <0.001
Transthoracic echocardiographic variables      
LA diameter (mm) 36±3 37±2 ns
% LVEF 65±2 63±2 ns
LVPW thickness (mm) 10.5±0.6 10.8±0.6 ns
LVS thickness (mm) 10.6±0.6 10.8±0.6 ns
LV EDD (mm) 47±3 48±4 ns
LV ESD (mm) 27±4 27±3 ns
TAPSE at rest (mm) 26±5 22±4 ns.
TAPSE at peak (mm) 36±8 32±5 ns.
dPAPs (mmHg) 33±10 20±8 p<0.001
Data are  presented mean±SD; FEV1: forced expiratory volume in  one second;  FVC: forced vital  capacity;  TLC: total  lung capacity;  VC: vital
capacity; IC: inspiratory capacity; FRC: functional residual capacity; RV: residual volume; DLCO: diffusion capacity of carbon monoxide; LA: left
atrium; LVEF: left ventricular ejection fraction; LVPW: left ventricular posterior wall; LVS: left ventricular septum; LVEDD: left ventricular end-
diastolic diameter; LVESD: left ventricular end-systolic diameter, TAPSE: tricusp annular plane systolic excursion; dPAPs: change of pulmonary
arterial systolic pressure during exercise
Right atrial pressure was estimated at rest by the response of the inferior vena cava to deep inspiration and was
assumed to be constant throughout exercise. With the trailing-edge to leading-edge technique, maximum inferior vena
cava diameters before inspiration and minimum diameters after inspiration were measured in the subcostal view within
2 cm of the entrance to the right atrium. When the diameter of the inferior vena cava decreased by less than 50% after
deep inspiration, the right atrial pressure was defined as 15 mmHg, and when the diameter decreased by more than
50%,  the  right  atrial  pressure  was  defined  as  5  mmHg [28].  This  technique,  which  assumes  that  the  estimated  RA
pressure remains constant during exercise, has been validated against simultaneous measurements of pulmonary artery
systolic  pressure  during  incremental  exercise  [29].  TAPSE  was  determined  and  registered  at  peak  exercise.
Measurements  were  recorded  with  simultaneous  electrocardiography.  All  data  were  stored  digitally  and  the
measurements were made off-line at the completion of each study. Echocardiographic studies were performed by an
experienced cardiac sonographer, who had no knowledge of the clinical data.
Inflammation marker determination
Systemic inflammation marker high sensitive CRP was determined from serum with an immunoassay method [30].
Statistical analysis
Groups  were  compared  by  Student’s  t-test  and  chi-square  test  in  case  of  continuous  and  categorical  variables,
respectively. Significance was accepted at p<0.05. Distribution around the mean was expressed ± S.D. Distributions
were tested for normality by Kolmogorov–Smirnov test and significance was accepted if p<0.05. Pearson correlations
with dPAPs (change of systolic pulmonary arterial pressure during exercise) and dPAPs/WR (work rate) (change of
systolic  pulmonary  arterial  pressure  during  exercise  per  equivalent  work  unit)  were  also  evaluated.  An  analysis  of
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covariance  (ANCOVA)  was  used  to  compare  the  dependence  of  some  variables  on  the  dPAPs  in  the  two  groups.
Stepwise linear discrimination analysis was performed to examine the significance of the two groups based on several
variables. In patients with COPD, two groups were separated based on systolic pulmonary arterial pressure increment.
The  cut-off  point  calculation  as  an  abnormal  pulmonary  hemodynamic  response  (dPAPs>22mmHg)  was  based  on
systolic  pulmonary  arterial  pressure  increment  during  exercise  using  an  equation  of  mean  pulmonary  pressure
(mPAP=PAPs x 0.61+2mmHg) [31] and 15 mmHg mPAP elevation during exercise in >50 year-old healthy subjects
was reported by Kovacs G et al. [32].
RESULTS
Demographics of the study subjects are presented in Table 1. Smoking history varied significantly between the two
groups. COPD patients had several co-morbidities, and few subjects in the age-matched control group had hypertension,
diabetes or hyperlipidemia (Table 1).
Lung  function  showed  severe  obstruction  and  hyperinflation  at  baseline  in  our  subjects  with  COPD (Table  2).
Resting transthoracic echocardiographic variables are presented in (Table 2).
Exercise  physiologic  variables  showed  reduced  peak  work  rate  (54±21%pred)  and  oxygen  uptake
(VO2:50±14%pred,  VO2/kg:60±17%pred)  with  not  high  ventilatory  equivalents  (VE/VO2:36±5,  VE/VCO2:39±7)  in
COPD. However, clinically important desaturation was not detected in COPD (Sat:93±2 vs. 91±4%).
Fig. (2). The increase of peak pulmonary arterial systolic pressure during exercise during semi-supine exercise echocardiography.
PAPs: pulmonary artery systolic pressure; *:p<0.05 peak vs. rest, #:p<0.05 COPD patients vs. non-COPD subjects, @:p<0.05 peak-
rest value difference between groups, error bars represents ±SE.
Systolic pulmonary artery pressure was significantly higher in the COPD group compared to the control subjects at
rest,  and the increase during exercise was significantly different  between the groups,  achieving higher value in the
COPD group (Fig 2). The right ventricular function (TAPSE value) was normal at rest and remained physiologic at
peak exercise in both groups (Table 2). The increment in the pulmonary arterial pressure during exercise correlated with
the systemic inflammation marker hsCRP (Fig 3). In 19 COPD patients, the PAPs increment (dPAPs) was above 22
mmHg, and hsCRP was 11.1±8.8 mg/L compared to the 8 patients with PAPs increment (dPAPs) below 22 mmHg and
lower hsCRP values (1.9±3.2 mg/L). The degree of obstruction (FEV1, FEV1/FVC) was not a predictor for the PAPs
rise  during  exercise  in  the  COPD  group  (Table  3).  In  the  lung  function  variables,  FVC  as  an  indirect  marker  of
hyperinflation correlated with dPAPs in the COPD group (Fig 4).
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Fig.  (3).  Correlation  between increment  of  peak pulmonary  artery  systolic  pressure  during exercise  and systemic  inflammatory
marker  in  patients  with  COPD.  dPAPs:  change  in  PAPs  during  exercise,  hsCRP:  high  sensitive  C-reactive  protein,  r2:  linear
regression correlation coefficient.
DISCUSSION
The pulmonary artery pressure response in a COPD and an age and a gender-matched control group was evaluated
during exercise. The pulmonary artery pressure was significantly higher at rest and increased more in COPD compared
to control age and gender-matched non-COPD subjects. The increase of pulmonary arterial pressure during exercise
correlated with the systemic inflammatory marker hsCRP, and also with FVC in patient with COPD.
Secondary pulmonary hypertension in COPD results from sustained vasoconstriction and structural alterations to the
pulmonary  vascular  bed.  The  major  stimuli  that  are  presumed  responsible  for  these  changes  are  chronic  alveolar
hypoxia, chronic inflammation and excessive shear stress [33]. Systemic or local inflammation may enhance the injury
of acinar structure. Regardless of the stimuli that cause pulmonary hypertension, the structural changes that are thought
to  underlie  the  increased  vascular  resistance  can  be  broadly  classified  into  two processes:  first,  remodelling  of  the
pulmonary resistance vessels and, second, a reduction in the total number of blood vessels in the lungs [33].
The serum CRP levels seem to correlate with the degree of systemic inflammation in COPD. A high level of CRP
can also indicate an increased risk of cardiovascular diseases [34]. The systemic effect on the vasculature in COPD may
also increase atherosclerosis induced stroke [35]. Indeed, the diastolic dysfunction related heart failure with E/A<1 and
higher hsCRP might be partially responsible for the development of PH in our study as well.
In patients with COPD, the concomitant features of hypercholesterolemia, obesity, diabetes mellitus, hypertension,
as a clinical feature of metabolic syndrome (a cause of systemic vascular disease) may also be accompanied by high
CRP  level  [36].  In  our  investigation,  many  patients  (about  50%)  suffered  from  hypertension,  and  many  had  both
hypertension and diabetes.
Pulmonary arterial pressure generally increases with age [32]. In healthy individuals, it is suggested that the normal
mean pulmonary arterial  pressure measured by right  heart  catheterization is  14.0 ± 3.3 mmHg at  rest,  and the age-
dependent (especially > 50 years) increment during exercise may achieve a mean pressure of 30 mmHg [32]. Age-
matched control subjects were involved in our investigation to exclude the age-dependent PH differences between the
COPD  and  the  non-COPD  groups.  In  accordance  with  previous  data  [37].  PAPs  increase  during  exercise  by
echocardiography  was  found  in  healthy  subjects  as  well.
Pulmonary vascular impairment, secondary pulmonary hypertension may partially be responsible for the reduced
oxygen uptake [38], exercise capacity and increased ventilatory equivalent for CO2. Analyzing gas exchange during
cardio-pulmonary exercise test offers potential explanations for exercise limitation [39]. Reduced exercise tolerance
with ventilatory inefficiency according to higher ventilatory equivalent for CO2 was detected in our COPD patients.
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Table 3. Pearson’s correlation between identified study variables and dPASP. dPASP/WR in the COPD group.
* Correlation is significant at the 0.05 level (2-tailed).
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; TLC: total lung capacity; VC: vital capacity; IC: inspiratory capacity;
FRC: functional residual capacity; RV: residual volume; DLCO: diffusion capacity of carbon monoxide; WR: work rate; VO2: oxygen uptake;
VO2/kg: specific aerobic capacity; VCO2: carbon-dioxide output; LAT: lactate anaerobic threshold; VEmax: maximal minute ventilation; VE/VO2:
ventilatory equivalent for O2; VE/VCO2: ventilatory equivalent for CO2; RER: respiratory exchange ratio; TAPSE: tricuspidal annular plane systolic
excursion; LVEF: left ventricular ejection fraction; PAPs: pulmonary artery systolic pressure; hsCRP: high-sensitive C-reactive protein.
  dPAPs dPAPs/WR 
Pearson’s 
Correlation 
Age 0.004 0.359 
BMI 0.268 0.107 
FEV1 (L) -0.290 -0.364 
FEV1ref% -0.072 -0.060 
FVC (L) -0.422(*) -0.425(*) 
FVCref% -0.175 -0.068 
FEV1/FVC (%) -0.010 -0.143 
TLC ref% -0.075 -0.066 
VC ref% -0.075 -0.057 
IC(L) -0.075 -0.242 
FRC (ref%) -0.234 -0.163 
DLCO (mL/mmHg/min) -0.179 -0.396(*) 
Wmax 0.021 -0.343 
VO2 (ref%) 0.084 -0.205 
VO2/kg (mL/kg/min) -0.183 -0.424(*) 
LAT (L/min) -0.164 -0.455(*) 
HR (1/min) 0.372 0.024 
VEmax (L/min) -0.093 -0.310 
VE/VO2 at AT 0.152 0.337 
VE/VCO2 at AT 0.169 0.377 
TAPSErest 0.107 -0.098 
TAPSEpeak 0.191 0.125 
LVEF (%) 0.047 0.135 
PAPsrest 0.192 0.229 
PAPspeak 0.917(**) 0.757(**) 
hsCRP 0.730(**) 0.510(**) 
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Exercise  echocardiography  in  semi-supine  position  can  be  used  to  assess  pulmonary  arterial  systolic  pressure
response  to  exercise  which  helps  in  better  understanding  the  functional  impairment  in  relation  to  dyspnoea  during
exertion.  This  type  of  non-invasive  assessment  of  pulmonary  hemodynamics  is  appropriate  for  early  detection  of
pathologic changes in the pulmonary vasculature [40]. In our study, all pulmonary arterial pressure measurements were
performed by only one experienced observer to eliminate the inter-observer variability.
Nevertheless, our study had limitations. Accurate measurement of pulmonary arterial pressure requires right heart
catheterisation. The measurement of pulmonary arterial systolic pressure by echo-cardiography may be limited during
exercise.  8  of  38  patients  with  COPD could  not  perform the  semi-supine  position  exercise  test,  and PAPs was  not
detectable in 3 of them. The evaluation of PAPs value by echocardiography in special cases might be higher during
exercise compared to direct PAPs measurement by right heart catheterisation [41]. Moreover, echocardiography results
in  false-positive  detection  of  pulmonary  hypertension  in  up  to  50%  of  COPD  patients  [42].  Correlation  analyses
between hsCRP, FVC and dPAPs could show potential associations but by no means do reflect causality.
The theory of systemic inflammation might be only one component related to elevated pulmonary arterial pressure
during  exercise  in  our  patients  with  COPD.  PH manifested  due  to  COPD and/or  hypoxia:  the  pathobiological  and
pathophysiological mechanisms involved in this setting are multiple and include hypoxic vasoconstriction, mechanical
stress of hyperinflated lungs, loss of capillaries, inflammation, and toxic effects of cigarette smoke. Moreover, there are
data supporting an endothelium-derived vasoconstrictor-vasodilator imbalance [43]. As hypertension was quite frequent
in both groups (52% and 38%), thereby left ventricular diastolic dysfunction might have contributed to PAPs elevation
during exercise. Hyperinflation might have also during exercise been involved in the increase of PAPs as there was a
negative correlation between numeric value of FVC and dPAPs.
Fig.  (4).  Correlation between increment of peak pulmonary artery systolic pressure during exercise and forced vital  capacity in
patients with COPD. dPAPs: change in PAPs during exercise, FVC: forced vital capacity, r2: linear regression correlation coefficient.
In summary, the pulmonary arterial pressure was higher at rest and increased significantly more during exercise in
COPD patients compared to non-COPD control subjects. The rate of pulmonary arterial pressure increment partially
correlated with the systemic inflammatory marker hsCRP. The increase in pulmonary arterial systolic pressure during
exercise may in part be related to systemic inflammation. In case of high PA pressures during exercise, in order to
maintain stroke volume the work of the right ventricle is disproportionally increased. Hemodynamic exercise testing
with Doppler echocardiography may contribute to our better understanding of the exercise limitations in COPD and
help define a more appropriate training program for the rehabilitation of patients with COPD.
LIST OF ABBREVIATIONS
ANCOVA = Analysis of covariance
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CO2 = Carbon-dioxide
COPD = Chronic obstructive pulmonary disease
CPET = Cardio-pulmonary exercise test
DLCO = Diffusion capacity for carbon monoxide
dPAPs = Change of systolic pulmonary arterial pressure during exercise
ECG = Electrocardiogram
EF = Ejection fraction
FEV1 = Forced expiratory volume in one second
FVC = Forced vital capacity
hsCRP = High sensitive C-reactive protein
LAT = Lactate anaerobic threshold
NHANES III = Third National Health and Nutrition Examination Survey
PA = Pulmonary artery
PAPs = Pulmonary arterial systolic pressure
PFT = Pulmonary function test
PH = Pulmonary hypertension
RA = Right atria
S.D. = Standard deviation
TAPSE = Tricuspid annular plane systolic excursion
V = Velocity
‘VE = Pulmonary ventilation
‘VCO2 = Carbon-dioxide output
‘VO2 = Oxygen uptake
VO2/kg = Specific aerob capacity
WR = Work rate
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